Validated LC-MS/MS assay for quantification of the newly approved tyrosine kinase inhibitor, dacomitinib, and application to investigating its metabolic stability

Dacomitinib (DMB) is a second-generation irreversible tyrosine kinase inhibitor (TKI) that is claimed to overcome the disadvantages of the resistance reported for first-line epidermal growth factor receptor (EGFR) TKIs. Towards the end of 2018, the US Food and Drug Administration approved DMB in the...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:PLoS One
Asıl Yazarlar: Abdelhameed, Ali S., Kadi, Adnan A., Attwa, Mohamed W., AlRabiah, Haitham
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Public Library of Science 2019
Konular:
Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6448865/
https://ncbi.nlm.nih.gov/pubmed/30947315
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0214598
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller